Home » Topics » Regulatory » Patents

Patents
RSS

EPO activators/agonists described by J&J and Affymax

Feb. 14, 1997

Neutrophil-stimulating peptides derived from TNF described by Peptech

Feb. 13, 1997

Pfizer claims 5-LO inhibitors

Feb. 13, 1997

Sugen reports modulators of tyrosine signal transduction

Feb. 13, 1997

Anticancer agents from Takeda

Feb. 13, 1997

Novel antiarrhythmic agents described by Merck & Co.

Feb. 13, 1997

AGE inhibitors reported by Kissei

Feb. 13, 1997

Sulfonamide derivatives for inhibition of cell adhesion

Feb. 12, 1997

American Home Products describes antiproliferative agents

Feb. 12, 1997

Dual PDE IV/TNF inhibitors from Pfizer

Feb. 12, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...